

Anti-tuberculosis Induced Stevens-Johnson Syndrome Due to Misdiagnosis of Mycobacterium Abscessus Urinary Tract Infection as Tuberculosis

Sara Abolghasemi,¹ Shahnaz Sali,¹ Arad Mobasher Aghdam,² Mohammad Amin Shahrbaft²

¹Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Keywords. mycobacterium tuberculosis, mycobacterium abscessus, urinary tract infection, steven-johnson syndrome

Mycobacterium abscessus complex is one of the most important groups of non-tuberculosis mycobacteria, which can cause infection in several organs of the human body. In this study, we report a rare cause of urinary tract infection which was presented with the chief complaint of hematuria and dysuria. The patient was treated by a clarithromycin based approach and the result of the culture and polymerase chain reaction were negative after 3 months of treatment. Informed consent was taken from the patient for publishing the case.

IJKD 2021;15:235-7
www.ijkd.org

INTRODUCTION

Non-tuberculosis mycobacteria (NTM) are microorganisms commonly found in the soil, tap water, domestic, wild animal, and food products.¹ There are more than 140 species of NTM which can be pathogen and cause different infections in humans.² The *mycobacterium abscessus* complex (MABC) is one of the most important groups of NTM which is increasing globally.³ MABC is one of the rapidly growing mycobacteria causing a variety of opportunistic infections in soft tissue, bone, skin and also disseminated infection.⁴

Urinary tract infection is one of the major causes of extra-pulmonary infection of tuberculosis.⁵ However, urinary tract infection caused by NTM is an extremely rare presentation.⁶ In this study, we report a complicated case of urinary tract infection, which is caused by *mycobacterium abscessus*.

CASE PRESENTATION

A 62-year-old male was presented to the infectious disease clinic with a chief complaint of dysuria and hematuria since a year ago. His history of underlying disease such as diabetes was unremarkable. The ultrasonography of kidney, ureter, and bladder (KUB) and urine analysis

(UA) were normal and therefore, the patient was referred to an infectious disease clinic for further assessment. The patient was treated as a case of recurrent urinary tract infection (UTI) for 7 months. Terminal hematuria was added to the patient's complaints and dysuria became more severe than before. Some evidences of bladder infection and left ureter obstruction were observed in further ultrasonography. A urinary smear for acid fast bacillus (AFB) was requested after stent insertion. The urinary smear was +3 positive for AFB. Treatment of urinary tuberculosis was started with fixed-dose drug combinations (pyrazinamide, isoniazid, rifampin, ethambutol, and pyridoxine). One week later, severe allergic reaction in the form of generalized pruritus, maculopapular, blisters and pustular skin rash, eye involvement and mucosal ulcers were observed. Hence, anti-tuberculosis drugs were discontinued and the patient was referred to our clinic with the primary diagnosis of Stevens-Johnson syndrome due to anti-tuberculosis drugs (Figure). For further investigation, urine PCR for mycobacterium tuberculosis and non-tuberculosis was requested. The result of PCR indicated the presence of mycobacterium abscessus in the urinary tract. Laboratory tests were as follows:



A) Conjunctivitis Which Seen After Stevens-Johnson Reaction,
B) Mucosal Ulcers of the Oral Cavity Which Caused by Stevens-Johnson Syndrome

complete blood count (CBC) and biochemical tests were normal. Human immunodeficiency virus antibody (HIV Ab) was negative. Chest X-ray was also unremarkable. The patient was admitted and treatment was started with the combination of amikacin (500 mg two times, daily) and imipenem (1 gram two times, daily) for 2 weeks. The patient's dysuria and hematuria were subsided just 8 days after starting the treatment. Then, the treatment was continued by clarithromycin for 6 months (500 mg two times, daily). The patient was followed up monthly by urine culture and after 3 months, the culture was negative for mycobacterium abscessus. Clarithromycin was continued 3 months after the negative result of culture and polymerase chain reaction (PCR).

DISCUSSION

In the current study, a patient who had urinary tract infection with mycobacterium abscessus was reported. To the best of our knowledge, mycobacterium abscessus UTI is extremely rare and there are only three cases in recent studies (two cases in one study).^{6,7}

MABc that causes opportunistic infections in human is highly resistant to treatment.⁸ These microorganisms are a group of rapidly growth NTM which, first were described in 1953.⁹

Immunocompromised and immunodeficient patients are more susceptible to these infections,¹⁰ however; the current case had no history of immunodeficiency or taking immunosuppressant drugs.

With regards to antibiotic resistance, treatment of the UTI caused by *mycobacterium abscessus* is a challenging issue. According to the Infectious Disease Society of America's recommendation, intravenous amikacin administration in combination with cefoxitin or imipenem is the best choice of treatment.¹¹ Furthermore, clarithromycin is also one of the therapeutic choices that has been used for the treatment of MABc since 1990s.¹² For extrapulmonary cases of MABc, 4 to 6 months treatment is recommended with the initial administration of amikacin and cefoxitin or imipenem for the first two weeks.¹³ However, due to the rarity of the current case, the treatment strategy was so important. For this case, we used intravenous amikacin and imipenem for the first two weeks; after that, we continued the treatment with oral clarithromycin for 4 to 6 months.

After 3 months, the result of urine culture was negative for MABc and the patient was discharged from the hospital. The patient was followed up for one year by a monthly visit in combination with a urine culture. In addition, Stevens-Johnson syndrome (SJS) after anti-tuberculosis drugs is a rare phenomenon and is often reported in immunodeficient patients.^{14,15} The case of this study was negative for HIV; moreover, we do not know exactly which anti-TB drug caused SJS in this case.

ACKNOWLEDGMENTS

The authors would like to thank Shahid Beheshti University of Medical Sciences and Labbafinejad Hospital for their support, cooperation, and assistance.

REFERENCES

1. Baker AW, Lewis SS, Alexander BD and et al. Two-phase hospital-associated outbreak of *Mycobacterium abscessus*: investigation and mitigation. *Clinical Infectious Diseases*. 2017; 64(7):902-11.
2. Porvaznik I, Solovič I, Mokry J. Non-tuberculous mycobacteria: classification, diagnostics, and therapy. *Respiratory Treatment and Prevention*: Springer. 2016. p. 19-25.
3. Kim S-W, Subhadra B, Whang J and et al. Clinical *Mycobacterium abscessus* strain inhibits autophagy

- flux and promotes its growth in murine macrophages. *Pathogens and disease*. 2017; 75(8).
4. Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts. *Clin Chest Med*. 2015; 36(1):91-9.
 5. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. *American family physician*. 2005; 72(9).
 6. Huang CT, Chen CY, Chen HY and et al. Genitourinary infections caused by nontuberculous mycobacteria at a university hospital in Taiwan, 1996–2008. *Clinical Microbiology and Infection*. 2010; 16(10):1585-90.
 7. Traoré B , Fongoro S, Timbiné LG and et al. Mycobacterium abscessus Urinary Infection in Hypertensive Patient: A Case Report. *Mycobacterial Diseases*. 2016; 6(4).
 8. Ryu YJ, Koh W-J, Daley CL. Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians' perspectives. *Tuberculosis and respiratory diseases*. 2016; 79(2):74-84.
 9. Moore M, Frerichs JB. An Unusual Acid-Fast Infection of the Knee with Subcutaneous, Abscess-Like Lesions of the Gluteal Region: Report of a Case with a Study of the Organism, *Mycobacterium abscessus*, n. sp. 1. *Journal of Investigative Dermatology*. 1953; 20(2):133-69.
 10. Sfeir M, Walsh M, Rosa R and et al., editors. *Mycobacterium abscessus Complex Infections: A Retrospective Cohort Study*. Open forum infectious diseases; 2018: Oxford University Press US.
 11. Griffith DE, Aksamit T, Brown-Elliott BA and et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *American journal of respiratory and critical care medicine*. 2007; 175(4):367-416.
 12. Devi DG, Mallikarjuna H, Chaturvedi A, Prasad SV. A Case of Meningitis Caused by *Mycobacterium abscessus* in a Paediatric Patient. *Journal of Tuberculosis Research*. 2015; 3(02):54.
 13. Jeong SH, Kim S-Y, Huh HJ, Ki C-S and et al. Mycobacteriological characteristics and treatment outcomes in extrapulmonary *Mycobacterium abscessus* complex infections. *International Journal of Infectious Diseases*. 2017; 60:49-56.
 14. Badar VA, Mishra D, Deshmukh S, Chaudhari S. A case of Stevens-Johnson syndrome due to rifampicin. *International Journal of Basic & Clinical Pharmacology*. 2017; 3(1):239-41.
 15. Wirima JJ, Harries AD. Stevens-Johnson syndrome during anti-tuberculosis chemotherapy in HIV-seropositive patients: report on six cases. *East African medical journal*. 1991; 68(1):64-6.

Correspondence to:
 Mohammad Amin Shahrbaaf, MD
 Koodakyar Dead-End, Velenjak Street, Postal Code: 19839-63113, Tehran, Iran
 Tel: 0098 918 910 4127
 E-mail: Aminshahrbaaf41@gmail.com

Received December 2020
 Revised February 2021
 Accepted March 2021